儿童神经母细胞瘤的放疗研究进展

贾海威; 张军

doi:10.12354/j.issn.1000-8179.2023.20221483

儿童神经母细胞瘤的放疗研究进展

doi: 10.12354/j.issn.1000-8179.2023.20221483

贾海威^,,
张军

北京丰台右安门医院放疗科（北京市100069）

详细信息

作者简介:
贾海威：专业方向为儿童肿瘤的放疗及综合治疗

通讯作者:
贾海威　13321120266@163.com

计量
- 文章访问数: 129
- HTML全文浏览量: 62
- PDF下载量: 44
- 被引次数: 0
出版历程
- 收稿日期: 2022-10-20
- 录用日期: 2022-12-29
- 修回日期: 2022-12-28

Research progress on radiotherapy for pediatric neuroblastoma

Haiwei Jia^,,
Jun Zhang

Department of Radiation Oncology, Beijing Fengtai Youanmen Hospital, Beijing 100069, China

More Information

Corresponding author: Haiwei Jia; E-mail: 13321120266@163.com

摘要

摘要: 在过去的几十年中，儿童神经母细胞瘤（neuroblastoma，NB）的放射治疗经历了不断的发展，确立了其在综合治疗中的作用。为了探索放疗在NB中的确切作用，有必要进行更多的前瞻性随机试验，以提供更多证据来指导制定最佳放疗方案。本文分析了NB的主要多机构前瞻性试验以及大型回顾性研究的证据，以确定当前的放疗标准和诸多争议；对放疗的适应证、辐射剂量分割、时间、靶区和治疗计划进行了回顾；总结了基于证据的共识，并讨论了有待解决的临床问题。
- 神经母细胞瘤 /
- 放疗 /
- 儿科
Abstract: Radiotherapy for pediatric neuroblastoma has undergone continuous evolution in recent decades to establish its role in combined modality management. Despite extensive clinical experience, the precise role of radiotherapy in neuroblastoma remains unclear. Its evolution is still far from over, and more prospective randomized trials are needed to provide more evidence to guide development of optimal radiotherapy treatment schedules. This review analyzes evidence from major multi-institutional prospective trials as well as large retrospective institutional series of neuroblastoma cases to determine the current radiotherapy standards and controversies. The indications for radiotherapy, radiation dose-fractionation, timing, target volumes, and treatment planning are reviewed. A summary of evidence-based consensus recommendations is presented, and unresolved aspects are discussed.
- neuroblastoma /
- radiotherapy /
- pediatrics

HTML全文

参考文献(35)

[1]	Irwin MS, Naranjo A, Zhang FF, et al. Revised neuroblastoma risk classification system: a report from the children's oncology group[J]. J Clin Oncol, 2021, 39(29):3229-3241.
[2]	Twist CJ, Schmidt ML, Naranjo A, et al. Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the children's oncology group study ANBL0531[J]. J Clin Oncol, 2019, 37(34):3243-3255. doi: 10.1200/JCO.19.00919
[3]	Hsu LL, Evans AE, D'Angio GJ. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate[J]. Med Pediatr Oncol, 1996, 27(6):521-528. doi: 10.1002/(SICI)1096-911X(199612)27:6<521::AID-MPO3>3.0.CO;2-N
[4]	Katzenstein HM, Kent PM, London WB, et al. Treatment and outcome of 83 children with intraspinal neuroblastoma: the pediatric oncology group experience[J]. J Clin Oncol, 2001, 19(4):1047-1055. doi: 10.1200/JCO.2001.19.4.1047
[5]	Fawzy M, El-Beltagy M, Shafei ME, et al. Intraspinal neuroblastoma: treatment options and neurological outcome of spinal cord compression[J]. Oncol Lett, 2015, 9(2):907-911. doi: 10.3892/ol.2014.2795
[6]	Tang J, Zhang D, Xu YY, et al. Clinical characteristics and therapeutic outcomes of mediastinal neuroblastoma with intraspinal extension: a retrospective study[J]. Transl Pediatr, 2021, 10(4):715-722. doi: 10.21037/tp-20-268
[7]	Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma[J]. N Engl J Med, 2010, 363(14):1313-1323. doi: 10.1056/NEJMoa1001527
[8]	Liang WH, Federico SA, London WB, et al. Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future[J]. JCO Clin Cancer Inform, 2020, 4:895-905.
[9]	Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a children's cancer group study[J]. Int J Radiat Oncol, 2003, 56(1):28-39. doi: 10.1016/S0360-3016(02)04506-6
[10]	Braunstein SE, London WB, Kreissman SG, et al. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: a report from the COG A3973 study[J]. Pediatr Blood Cancer, 2019, 66(7):e27736. doi: 10.1002/pbc.27736
[11]	Jazmati D, Butzer S, Hero B, et al. Proton beam therapy for children with neuroblastoma: experiences from the prospective kiproreg registry[J]. Front Oncol, 2020, 10:617506.
[12]	Liu KX, Naranjo A, Zhang FF, et al. Prospective evaluation of radiation dose escalation in patients with high-risk neuroblastoma and gross residual disease after surgery: a report from the children's oncology group ANBL0532 study[J]. J Clin Oncol, 2020, 38(24):2741-2752.
[13]	Rosen EM, Cassady JR, Frantz CN, et al. Neuroblastoma: the joint center for radiation therapy/Dana-farber cancer institute/children's hospital experience[J]. J Clin Oncol, 1984, 2(7):719-732.
[14]	Hattangadi JA, Rombi B, Yock TI, et al. Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison[J]. Int J Radiat Oncol, 2012, 83(3):1015-1022. doi: 10.1016/j.ijrobp.2011.08.035
[15]	Pai Panandiker AS, Beltran C, Billups CA, et al. Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma[J]. Pediatr Blood Cancer, 2013, 60(5):761-765. doi: 10.1002/pbc.24350
[16]	Bradfield SM, Douglas JG, Hawkins DS, et al. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma[J]. Cancer, 2004, 100(6):1268-1275. doi: 10.1002/cncr.20091
[17]	Wei ZX, Li J, Jin Y, et al. The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma[J]. Br J Radiol, 2022, 95(1134):20211086. doi: 10.1259/bjr.20211086
[18]	Pai Panandiker AS, McGregor L, Krasin MJ, et al. Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma[J]. Int J Radiat Oncol Biol Phys, 2010, 76(4):1161-1165. doi: 10.1016/j.ijrobp.2009.03.068
[19]	De Ioris MA, Crocoli A, Contoli B, et al. Local control in metastatic neuroblastoma in children over 1 year of age[J]. BMC Cancer, 2015, 15:79. doi: 10.1186/s12885-015-1082-7
[20]	Sibley GS, Mundt AJ, Goldman S, et al. Patterns of failure following total body irradiation and bone marrow transplantation with or without a radiotherapy boost for advanced neuroblastoma[J]. Int J Radiat Oncol Biol Phys, 1995, 32(4):1127-1135. doi: 10.1016/0360-3016(95)00011-M
[21]	Gatcombe HG, Marcus RB Jr, Katzenstein HM, et al. Excellent local control from radiation therapy for high-risk neuroblastoma[J]. Int J Radiat Oncol Biol Phys, 2009, 74(5):1549-1554. doi: 10.1016/j.ijrobp.2008.10.069
[22]	Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery[J]. J Clin Oncol, 2001, 19(11):2821-2828. doi: 10.1200/JCO.2001.19.11.2821
[23]	Casey DL, Kushner BH, Cheung NK, et al. Local control with 21-gy radiation therapy for high-risk neuroblastoma[J]. Int J Radiat Oncol Biol Phys, 2016, 96(2):393-400. doi: 10.1016/j.ijrobp.2016.05.020
[24]	Casey DL, Kushner BH, Cheung NV, et al. Reduced-dose radiation therapy to the primary site is effective for high-risk neuroblastoma: results from a prospective trial[J]. Int J Radiat Oncol Biol Phys, 2019, 104(2):409-414. doi: 10.1016/j.ijrobp.2019.02.004
[25]	Robbins JR, Krasin MJ, Pai Panandiker AS, et al. Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience[J]. J Pediatr Surg, 2010, 45(4):678-686. doi: 10.1016/j.jpedsurg.2009.11.003
[26]	Casey DL, Kushner BH, Cheung NV, et al. Dose-escalation is needed for gross disease in high-risk neuroblastoma[J]. Pediatr Blood Cancer, 2018, 65(7):e27009. doi: 10.1002/pbc.27009
[27]	Simon T, Hero B, Bongartz R, et al. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 year with residual local disease[J]. Strahlenther Onkol, 2006, 182(7):389-394.
[28]	Berthold F, Faldum A, Ernst A, et al. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR[J]. Ann Oncol, 2020, 31(3):422-429. doi: 10.1016/j.annonc.2019.11.011
[29]	Ferris MJ, Danish H, Switchenko JM, et al. Favorable local control from consolidative radiation therapy in high-risk neuroblastoma despite gross residual disease, positive margins, or nodal involvement[J]. Int J Radiat Oncol Biol Phys, 2017, 97(4):806-812. doi: 10.1016/j.ijrobp.2016.11.043
[30]	Mazloom A, Louis CU, Nuchtern J, et al. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma[J]. Int J Radiat Oncol Biol Phys, 2014, 90(4):858-862. doi: 10.1016/j.ijrobp.2014.07.019
[31]	Polishchuk AL, Li R, Hill-Kayser C, et al. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma[J]. Int J Radiat Oncol Biol Phys, 2014, 89(4):839-845. doi: 10.1016/j.ijrobp.2014.04.004
[32]	Casey DL, Pitter KL, Kushner BH, et al. Radiation therapy to sites of metastatic disease as part of consolidation in high-risk neuroblastoma: can long-term control Be achieved[J]? Int J Radiat Oncol Biol Phys, 2018, 100(5):1204-1209.
[33]	Lucas JT Jr, Wakefield DV, Doubrovin M, et al. Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma[J]. Clin Transl Radiat Oncol, 2022, 34:42-50. doi: 10.1016/j.ctro.2022.02.009
[34]	Kandula S, Prabhu RS, Nanda R, et al. Outcomes after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma[J]. J Pediatr Hematol Oncol, 2015, 37(3):175-180.
[35]	Jazmati D, Butzer S, Hero B, et al. Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004[J]. Strahlenther Onkol, 2021, 197(8):683-689. doi: 10.1007/s00066-020-01718-5